Login

Consolidated balance sheets

In millions of USD, except per-share amounts
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q3 FY2020
As of Sep 30, 2020
Q2 FY2020
As of Jun 30, 2020
Q1 FY2020
As of Mar 31, 2020
Assets
Current assets
Cash and cash equivalents
Restricted cash and cash equivalents
Accounts receivable, net
Inventory
Prepaid expenses and other current assets
Assets subject to assignment for the benefit of creditors, current portion
Total current assets
Restricted cash and cash equivalents
Long-term deposits
Property, plant and equipment, net
Intangible assets, net
Investment in affiliate
Goodwill
Prepayment - long-term supply agreement
Other assets
Assets subject to assignment for the benefit of creditors
Total assets
Liabilities and stockholders' equity
Current liabilities
Accounts payable
Accrued expenses and other current liabilities
Finance lease liabilities, current
Debt and finance lease liabilities, current
Liabilities subject to assignment for the benefit of creditors, current portion
Total current liabilities
Finance lease liabilities
Long-term debt and finance lease liabilities, net of current portion
Operating lease liabilities
Warrant liability
Estimated liability - guarantee of obligation of unconsolidated affiliate
Other long-term liabilities
Deferred tax liabilities, net
Liabilities subject to assignment for the benefit of creditors
Total liabilities
Common stock issued for investment in affiliates including common stock subject to Put Right
Stockholders' equity
Preferred stock, $0.0001 par value, 150,000,000 shares authorized, no shares issued and outstanding as of December 31, 2024 and 2023
Common stock, $0.0001 par value, 1,000,000,000 and 1,600,000,000 shares authorized as of December 31, 2024 and 2023, respectively, 115,639,591 and 44,336,100 shares issued and outstanding as of December 31, 2024 and 2023, respectively (1)
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders' equity
Total liabilities and stockholders' equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support